Form S-3 - Registration statement under Securities Act of 1933:
SEC Accession No. 0001104659-25-040270
Filing Date
2025-04-28
Accepted
2025-04-28 17:00:54
Documents
9

Document Format Files

Seq Description Document Type Size
1 FORM S-3 tm2512766d1_s3.htm S-3 286501
2 EXHIBIT 4.3 tm2512766d1_ex4-3.htm EX-4.3 366558
3 EXHIBIT 4.4 tm2512766d1_ex4-4.htm EX-4.4 349475
4 EXHIBIT 5.1 tm2512766d1_ex5-1.htm EX-5.1 28022
5 EXHIBIT 23.1 tm2512766d1_ex23-1.htm EX-23.1 3999
6 EX-FILING FEES tm2512766d1_ex-filingfees.htm EX-FILING FEES 34185
7 GRAPHIC image_001.jpg GRAPHIC 3738
8 GRAPHIC tm2512766d1_s3img001.jpg GRAPHIC 6625
9 GRAPHIC tm2512766d1_ex5-1img001.jpg GRAPHIC 9278
  Complete submission text file 0001104659-25-040270.txt   1097502
Mailing Address 2 UNIVERSITY PLAZA SUITE 100 HACKENSACK NJ 07601
Business Address 2 UNIVERSITY PLAZA SUITE 100 HACKENSACK NJ 07601 201-696-9345
Protalix BioTherapeutics, Inc. (Filer) CIK: 0001006281 (see all company filings)

EIN.: 650643773 | State of Incorp.: DE | Fiscal Year End: 1231
Type: S-3 | Act: 33 | File No.: 333-286802 | Film No.: 25881372
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)